Trials / Completed
CompletedNCT05894928
A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
A Phase 1 Study to Investigate the Effect of Cholestyramine on the Pharmacokinetics of LOXO-783 in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to conduct blood tests to measure how much LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered alone or in combination with cholestyramine in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783 with and without cholestyramine. Participation could last up to 63 days including screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LOXO-783 | Administered orally. |
| DRUG | Cholestyramine | Administered orally. |
Timeline
- Start date
- 2023-06-07
- Primary completion
- 2023-07-09
- Completion
- 2023-07-09
- First posted
- 2023-06-08
- Last updated
- 2023-09-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05894928. Inclusion in this directory is not an endorsement.